Prednimustine
Chemical compound
- L01AA08 (WHO)
- [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate
- 29069-24-7 Y
- 34457
- 31708 N
- 9403SIO2S8
- C19512 Y
- DTXSID4021183
- Interactive image
- C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCCc4ccc(cc4)N(CCCl)CCCl)O)CCC5=CC(=O)C=C[C@]35C)O
InChI
- InChI=1S/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3/t27-,28-,29-,32+,33-,34-,35-/m0/s1 N
- Key:HFVNWDWLWUCIHC-GUPDPFMOSA-N N
Prednimustine, sold under the brand names Mostarina and Sterecyst, is a medication which is used in chemotherapy in the treatment of leukemias and lymphomas.[1][2][3] It is the ester formed from two other drugs, prednisolone and chlorambucil.[1][2][3] Rarely, it has been associated with myoclonus.[4]
See also
References
- ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1012–. ISBN 978-1-4757-2085-3.
- ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 868–. ISBN 978-3-88763-075-1.
- ^ a b Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 230–. ISBN 978-94-011-4439-1.
- ^ Monnerat C, Gander M, Leyvraz S (January 1997). "A rare case of prednimustine-induced myoclonus". Journal of the National Cancer Institute. 89 (2): 173–174. doi:10.1093/jnci/89.2.173. PMID 8998190.
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e